Rose Conway Walsh (Sinn Fein) | Oireachtas source

As Ms McGrath knows, in many of these cases, time is the one thing we do not have. I have significant issues with the cost because it is not negotiated. We are taking a headline cost and working out the cost-benefit analysis on that basis but we cannot hope to do so when the drug company is giving a cost expecting it to be negotiated, and rightly so - it would happen in any business negotiation - but it is not being negotiated by the HSE. How can we hope to have an outcome that would be positive in that situation?